Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

BACKGROUND: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-α/δ activity that has demonstrated clinical activity and manageable safety when administered as monotherapy in a phase II study. Combination therapy may overcome compensatory signalling that...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, R D, Alberts, S R, Peña, C, Genvresse, I, Ajavon-Hartmann, A, Xia, C, Kelly, A, Grilley-Olson, J E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830590/
https://www.ncbi.nlm.nih.gov/pubmed/29348486
http://dx.doi.org/10.1038/bjc.2017.428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830590/
https://www.ncbi.nlm.nih.gov/pubmed/29348486
http://dx.doi.org/10.1038/bjc.2017.428

Ejemplares similares